Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

NCT00337883 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00337883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00337883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2003
Completion date
October 31, 2005
Enrollment
110
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma